CC
EW icon

Claybrook Capital’s Edwards Lifesciences EW Stock Holding History

Claybrook Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,846
Closed -$398K – 162
2021
Q2 		$398K Buy
+3,846
New +$363K 0.13% 120
2019
Q1 		– Sell
-3,057
Closed -$156K – 278
2018
Q4 		$156K Buy
+3,057
New +$155K 0.04% 157

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Claybrook Capital's EW Position: Q3 2021 in Review

Claybrook Capital sold out of Edwards Lifesciences (EW) in Q3 2021, closing a stake of 3,846 shares — an estimated $398K sold.

Claybrook Capital first reported a position in EW in Q4 2018 and held it in 2 quarters. The position peaked at $398K in Q2 2021. 1,227 funds tracked by Wall St. Rank hold EW as of Q3 2021.

  • Claybrook Capital reported no remaining Edwards Lifesciences position as of Q3 2021 after selling out during the quarter.
  • Claybrook Capital sold 3,846 Edwards Lifesciences shares in Q3 2021, an estimated $398K.
  • Claybrook Capital first reported a position in Edwards Lifesciences in Q4 2018 and held it in 2 quarters.
  • Claybrook Capital's Edwards Lifesciences position peaked at $398K in Q2 2021.
  • 1,227 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.